Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rulonilimab plus Lenvatinib in Advanced HCC
NCT05408221Phase 3Recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rulonilimab in hepatocellular carcinoma (HCC), sponsored by Shandong New Time Pharmaceutical. Started Nov 2022; status: recruiting.
02
Drugs
rulonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05408221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408221.